Back to search

Article

Cytokine Release Syndrome–Compatible Fever After Initiation of Local Radiotherapy During Late-Phase Epcoritamab Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Report

2026-03-13

Abstract excerpt

<title>Abstract</title> <p> <bold>Background</bold> Epcoritamab, a subcutaneous CD3×CD20 bispecific antibody, has demonstrated promising activity in relapsed or refractory diffuse large B‑cell lymphoma. Cytokine release syndrome is a key adverse event associated with T‑cell–engaging therapies; however, it typically occurs early after treatment initiation and is generally manageable with step‑up dosing and preme...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0bb7339e-4a35-555a-aa37-d4e7e8cc253e
DOI
10.21203/rs.3.rs-9059446/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Cytokine Release Syndrome–Compatible Fever After Initiation of Local Radiotherapy During Late-Phase Epcoritamab Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case ReportDOI 10.21203/rs.3.rs-9059446/v1
Select a neighboring publication to make it the new centre.